EMG
SYRS

Ellington Management Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ellington Management Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,540
Closed -$227K – 847
2017
Q3 		$227K Buy
+1,540
New +$290K 0.04% 485

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Ellington Management Group's SYRS Position: Q4 2017 in Review

Ellington Management Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2017, closing a stake of 1,540 shares — an estimated $227K sold.

Ellington Management Group first reported a position in SYRS in Q3 2017 and held it in 1 quarter. The position peaked at $227K in Q3 2017. 69 funds tracked by Wall St. Rank hold SYRS as of Q4 2017.

  • Ellington Management Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 1,540 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $227K.
  • Ellington Management Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Ellington Management Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $227K in Q3 2017.
  • 69 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.